Table 1.
Characteristics of study patients (n = 60)
| Number | ||
|---|---|---|
| Mean age, years (range) | 53.0 (24.2–78.7) | |
| Sex | Male | 31 (51.7 %) |
| Female | 29 (48.3 %) | |
| Diabetes mellitus | 8 (13.3 %) | |
| Blood glucose level, mg/dl, mean (range) | Baseline | 100.9 (73–152) |
| Interim | 101.5 (80–190) | |
| Final | 104.7 (74–185) | |
| Serum AST/ALT, U/l, mean (range) | Before baseline | 23.0 (11–57)/22.5 (7–65) |
| Before interim PET | 21.6 (8–53)/26.0 (6–109) | |
| Before final PET | 25.4 (12–56)/28.9 (5–92) | |
| Mean initial LVEF % (range) | 64.6 (55–75) | |
| Use of dexrazoxane | Prior to interim scan | 5 (8.3 %) |
| Prior to final scan | 7 (11.7 %) | |
| Cumulative dose of doxorubicin, mg/m2, mean (range) | Prior to interim scan | 149.8 (138.1–158.4) |
| Prior to final scan | 299.7 (289.1–310.6) | |
| Time interval from chemotherapy, days, mean (range) | Prior to interim scan | 16.3 (6.6–28.4) |
| Prior to final scan | 16.8 (7.8–26.8) |
AST aspartate aminotransferase, ALT alanine aminotransferase, LVEF left ventricle ejection fraction